City of Hope, Leading Cancer Research and Treatment Center, to Provide First-Ever FDA-Approved CAR-T Cell … – Business Wire (press release)
|
City of Hope, Leading Cancer Research and Treatment Center, to Provide First-Ever FDA-Approved CAR–T Cell …
Business Wire (press release) Axicabtagene ciloleucel, a Kite Pharma Inc. product, is a therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein found on the cell surface of NHL as well as other lymphoma … |
